DUBLIN, June 17, 2022 /PRNewswire/ — “Global CAR T Cell Therapy Market Opportunity & Clinical Pipeline Insight 2028” drug pipelines have been added to from ResearchAndMarkets.com offer.

Global CAR T Cell Therapy Market Opportunity Expected to Exceed 15 billion US dollars by 2028

The development of CAR T cell therapy will gain momentum thanks to the growing number of investors, developers and analysts in guide therapy.

Rising cancer frequencies across the globe coupled with relentless technological advancements for reliable and effective cancer treatment is expected to support the growth of the global CAR-T cell therapy market. Additionally, heavy investment in clinical research and cell therapy development is expected to drive the CAR-T cell therapy market in the coming years.

The report provides information on globally approved CAR T cell therapies along with their price, dosage and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market.

The report offers a wide-ranging exploration of market dynamics and factors that are manipulating the growth of the global CAR-T Cell Therapy market. The report also gives a competitive analysis of major market players that will give a competitive edge to clients in their respective businesses.

Chimeric antigen receptor (CAR) T cell therapy is a new immunotherapeutic approach indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which T cells are taken from the patient’s blood, which are then modified in the laboratory by adding a gene for an artificial receptor (chimeric antigen receptor).

This helps to better recognize the specific antigens of cancer cells. The CAR T cells are then returned to the patient. To date, 6 CAR T cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel) have been approved by the FDA for the management of a wide range of cancers. Additionally, Relmacabtagene autoleucel has been approved in China.

The introduction of CAR T cell therapies showed high adoption rates in a short period of time propelled new research and development activities in this field. Apart from hematological malignancies, researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the market growth.

For example, a recent research study demonstrated that infusing patients with immune cells showed early promise in shrinking tumors in the digestive system. Interim results have shown that the tumors of almost 50% of the 37 patients so far have shrunk in size after therapy.

The global CAR T cell therapy market is highly consolidated with several key players. Pharmaceutical giants in the market are increasingly partnering or collaborating with technology companies to integrate advanced technologies for the improvement of CAR-T therapy or to expand their geographic presence.

For example, Bayer and Atara Biotherapeutics have entered into a global licensing agreement for the development of next-generation ATA3271, which is a mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the treatment of highly mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small cell lung cancer.

Among the drug types, Yescarta currently dominates the market. Yescarta (axicabtagene ciloleucel) is a genetically engineered autologous T-cell immunotherapy directed against CD19 indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse lymphoma large B cells.

Recently, in 2022, regulatory agencies expanded drug approvals for the management of large B-cell lymphoma (LBCL) refractory to first-line chemoimmunotherapy or relapsing within one year of first-line chemotherapy intention. The wide range of therapeutic indications as well as the worldwide availability of the drug are the main factors that are the main factors contributing to the dominance of these factors.

Report Highlights:

• Research Methodology
• Global CAR T Cell Therapy Market Opportunity > $15 billion
• Global and Regional Market Overview: Current and Market Forecast 2028
• CAR T Cell Therapies Approved Sales Forecast to 2028
• Emerging in vivo induced CAR T therapies
• CAR T Cell Therapy Manufacturing Cost Analysis
• CAR T Cell Therapy Approval and Reimbursement Scenario by Country
• Overview of Patents, Prices and Sales on 6 Approved CAR T Cell Therapies
• Overview of over 600 CAR T cell therapies in clinical trials
• CAR T Cell Therapies Clinical Trial Overview by Company, Country and Phase

Main topics covered:

1. Research methodology

2. Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno-Oncology

3. Evolution of the Chimeric Antigen Receptor (CAR) T Cell Design
3.1 Structure of the CAR-T cell
3.2 1st generation chimeric antigen receptor
3.3 2nd and 3rd generation CAR-T cell
3.4 Principle of design of chimeric antigen receptors

4. Approaches to improve the efficacy of CAR-T cell therapy

5. CAR T Cell Therapy Manufacturing Cost Analysis

6. Emerging in vivo induced CAR T therapies
6.1 Need for in vivo CAR T cell therapy
6.2 CAR T cell platform in vivo; VivoVec, TumorTag and RACR/CAR
6.3 Key drug in research and development

7. Global CAR T Cell Therapy Market Outlook 2022-2028
7.1 Market Overview
7.2 Future Market Opportunity

8. Globally Approved CAR T Cell Therapies – Price, Dosage and Sales Analysis 2028
8.1 Tisagenlecleucel (Kymriah)
8.2 Axicabtagen Ciloleuce (Yescarta)
8.3 Brexucabtagen Autoleucel (Tecartus)
8.4 Lisocabtagene maraleucel (Breyanzi)
8.5 Idecabtagene Vicleucel (Abecma)
8.6 Relmacabtagene autoleucel (Carteyva)
8.7 Autoleucel of ciltacabtagen (Carvykti)

9. US CAR T Cell Therapy Market Outlook
9.1 Approved and Key CAR T Cell Therapy Products in United States
9.2 Market Overview
9.3 Current reimbursement scenario

10. Europe CAR T Cell Therapy Market Outlook
10.1 Approved and Key CAR T Cell Therapy Products in Europe
10.2 United Kingdom
10.3 Germany
10.4 Spain
10.5 France
10.6 Rest of Europe
10.7 Current repayment scenario

11. China CAR T Cell Therapy Market Outlook
11.1 Approved and Key CAR T Cell Therapy Products in China
11.2 Current Market Size and Forecast

12. Japan CAR T Cell Therapy Market Outlook
12.1 Approved and Key CAR T Cell Therapy Products in Japan
12.2 Market Overview
12.3 Current reimbursement scenario

13. South Korea CAR T Cell Therapy Market Outlook
13.1 Approved and Key CAR T Cell Therapies in South Korea
13.2 Future Market Opportunity

14. Australia CAR T Cell Therapy Market Outlook
14.1 Approved and Key CAR T Cell Products in Australia
14.2 Australia CAR T Cell Therapy Market
14.3 Current repayment scenario

15. Taiwan CAR T Cell Therapy Market Outlook

16. Global CAR T Cell Clinical Pipeline Overview
16.1 By Company
16.2 By county
16.3 By indication
16.4 Phased

17. Global CAR T Cell Clinical Pipeline by Company, Indication and Phase
17.1 Research
17.2 Preclinical
17.3 Clinic
17.4 Phase I
17.5 Phase I/II
17.6 Phase II
17.7 Stage III
17.8 Registered

18. Marketed CAR T Cell Therapy Clinical Overview
18.1 Breyanzi
18.2 CARVYKTI
18.3 Yescarta
18.4 Kymriah
18.5 Abecma
18.6 Tecartus

19. Global CAR-T Cell Therapy Market Dynamics
19.1 Favorable parameters
19.2 Market Challenges

20. Competitive landscape
20.1 Autolus
20.2 Bellic
20.3 Bluebird
20.4 Celgene
20.5 Cellectis
20.6 Celiad
20.7 Eureka Therapy
20.8 Biotech Fortress
20.9 Immune therapy
20.10 Juno Therapeutic
20.11 Kite Pharma
20.12 Novartis
20.13 Therapeutic of Sorrento
20.14 TILT Biotherapeutic
20.15 Ziopharm

For more information about this Drug Pipelines report, visit https://www.researchandmarkets.com/r/lwj8p4

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets